Jim Simons Arcturus Therapeutics Holdings Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$17.71 - $32.97 $3 Million - $5.59 Million	-169,498 Reduced 94.32%	10,202 $322,000
Q3 2023 Nov 14, 2023	SELL	$25.44 - $37.35 $2.19 Million - $3.21 Million	-86,000 Reduced 32.37%	179,700 $4.59 Million
Q2 2023 Aug 11, 2023	BUY	$23.94 - $32.36 $6.36 Million - $8.6 Million	265,700 New	265,700 $7.62 Million
Q1 2022 May 13, 2022	SELL	$17.64 - $39.57 $470,758 - $1.06 Million	-26,687 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$34.2 - $47.56 $912,695 - $1.27 Million	26,687 New	26,687 $988,000
Q3 2021 Nov 12, 2021	SELL	$27.88 - $58.25 $822,460 - $1.72 Million	-29,500 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$25.79 - $42.11 $2.92 Million - $4.77 Million	-113,300 Reduced 79.34%	29,500 $998,000
Q1 2021 May 13, 2021	BUY	$38.75 - $86.92 $5.53 Million - $12.4 Million	142,800 New	142,800 $5.9 Million
Q1 2020 May 14, 2020	SELL	$9.31 - $18.26 $216,923 - $425,458	-23,300 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$8.93 - $12.41 $82,156 - $114,172	-9,200 Reduced 28.31%	23,300 $253,000
Q3 2019 Nov 13, 2019	BUY	$8.8 - $14.5 $286,000 - $471,250	32,500 New	32,500 $334,000

179

25.6M

195K

133K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $439M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.